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Without a doubt, our current antimicrobials are losing the battle in the fight against
newly-emerged multidrug-resistant pathogens. There is a pressing, unmet need for novel
antimicrobials and novel approaches to develop them; however, it is becoming increasingly
difficult and costly to develop new antimicrobials. One strategy to reduce the time and
cost associated with antimicrobial innovation is drug repurposing, which is to find new
applications outside the scope of the original medical indication of the drug. Ebselen, an
organoselenium clinical molecule, possesses potent antimicrobial activity against clinical
multidrug-resistant Gram-positive pathogens, including Staphylococcus, Streptococcus,
and Enterococcus, but not against Gram-negative pathogens. Moreover, the activity of
ebselen against Gram-positive pathogens exceeded those activities determined for vancomycin and linezolid, drugs of choice for treatment of Enterococcus and Staphylococcus
infections. The minimum inhibitory concentrations of ebselen at which 90% of clinical isolates of Enterococcus and Staphylococcus were inhibited (MIC90) were found to be 0.5 and
0.25 mg/L, respectively. Ebselen showed significant clearance of intracellular methicillinresistant S. aureus (MRSA) in comparison to vancomycin and linezolid. We demonstrated
that ebselen inhibits the bacterial translation process without affecting mitochondrial biogenesis. Additionally, ebselen was found to exhibit excellent activity in vivo in a Caenorhabditis elegans MRSA-infected whole animal model. Finally, ebselen showed synergistic
activities with conventional antimicrobials against MRSA. Taken together, our results
demonstrate that ebselen, with its potent antimicrobial activity and safety profiles, can be
potentially used to treat multidrug resistant Gram-positive bacterial infections alone or in
combination with other antibiotics and should be further clinically evaluated.

Introduction
Infections caused by Gram-positive drug-resistant pathogens are a leading cause of mortality.
Three species—methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae
and vancomycin-resistant enterococcus (VRE)—are responsible annually for at least 84% of
the antibiotic-resistant bacteria mortality in the United States alone. Further exacerbating the
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issue of bacterial resistance is the slow rate of the development and approval of new antimicrobials. For almost 80 years, antimicrobials have been crucial allies in the treatment of bacterial
infections caused by these pathogens. However, multidrug resistant strains have recently
emerged that are resistant to almost all antimicrobials once deemed effective, including fluoroquinolones, macrolides, and β-lactams [1]. Collectively, this points to an urgent need for the
discovery of new antimicrobials and novel strategies to develop them. One novel strategy that
warrants more attention as a unique method for development of new antimicrobials is drug
repurposing [2]. Our recent attempt to identify non-antibiotic drugs with potent antimicrobial
activity, within an applicable clinical range, identified organoselenium compound ebselen (EB)
as having potent antibacterial activities against Gram-positive pathogens [3, 4]. EB is considered a clinically safe molecule but without proven use yet [5]. It has anti-oxidative, anti-inflammatory, and anti-atherosclerotic properties [6]. Additionally, EB has been shown to exhibit
antimicrobial activity in vitro and in vivo [3, 4, 7–9]. EB exhibited antimicrobial activity by
inhibition of thioredoxin reducatse (TrxR) enzyme of Escherichia coli and H+-ATPase function
and proton-translocation function in yeast [7, 8, 10]. However, the antibacterial mechanism of
action of EB against Gram-positive bacteria remains unidentified [8].
The potent antimicrobial activity of EB against Gram-positive pathogens motivated us to
further investigate the therapeutic applications of EB. The aims of the present study are to
investigate the antibacterial activity of EB against Gram-positive clinical pathogens, including
MRSA and VRE in vitro, to identify antibacterial mechanism of action, to analyze the ability of
EB to clear MRSA intracellular infection, to evaluate antibacterial efficacy in MRSA-infected
Caenorhabditis elegans whole animal models, to evaluate the effect on mitochondrial biogenesis and toxicity in C. elegans, and to assess whether EB is capable of working synergistically
with conventional antibiotics against MRSA in in vitro and in infected cell cultures. This study
provided valuable insights into potential therapeutic applications of EB for use as antimicrobial
agents for the treatment of multidrug-resistant Gram-positive infections.

Materials and Methods
Bacterial strains and reagents
Bacterial strains employed in this study are presented in Table 1. Mannitol salt agar (MSA) was
purchased from Hardy Diagnostics (Santa Maria, CA). Muller-Hinton broth (MHB) was purchased from Sigma-Aldrich (St. Louis, MO). Trypticase soy broth (TSB) and Trypticase soy
agar (TSA) were purchased from Becton, Dickinson (Cockeysville, MD). EB was purchased
from (Adipogen corp, San Diego), vancomycin hydrochloride (Gold Biotechnology, St. Louis,
MO), linezolid (Selleck Chemicals, Houston, TX), clindamycin (TCI chemicals, Portland, OR),
erythromycin, rifampicin, ampicillin, gentamicin, chloramphenicol and fetal bovine serum
(FBS) were purchased from Sigma-Aldrich (St. Louis, MO). DMEM media were purchased
from Life technologies and MTS reagent (Promega, Madison, WI, USA).

In vitro antibacterial assays
Minimum inhibitory concentrations (MICs) were evaluated using micro dilution broth as per
the standards of Clinical and Laboratory Standards Institute (CLSI) [11]. MICs of drugs were
interpreted as the lowest concentration of the drug which inhibits the growth of bacteria after
incubating for at least 16–24 h at 37°C. The minimum bactericidal concentration (MBC) was
determined by sub-culturing 10 μl from the wells were no growth was observed onto TSA
plates. The plates were incubated for 24 h before the MBCs were determined. The MBC was
categorized as the concentration where ⩾99.9% reduction in bacterial cell count was observed
[1].
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Table 1. The MIC and MBC of EB against Gram-positive and Gram-negative bacteria.
Bacterial Strains

Strain ID

Source

Phenotypic Characteristics

MIC/MBC
(μg/ml)

Enterococcus spp

E. faecalis ATCC49533

Blood, Wisconsin

Resistant to streptomycin

0.25/8

E. faecalis ATCC7080

Meat involved in food
poisoning, New York

-

0.25/8

E. faecalis ATCC49532

Blood, Wisconsin

Resistant to gentamicin

0.25/8

E. faecalis ATCC14506

Quality control strain

-

0.5/8

E. faecalis ATCC 51229
(VRE)

Peritoneal ﬂuid, St. Louis, MO

Resistant to vancomycin. Sensitive to teichoplanin

0.5/0.5

E. faecalis SF24397

Urine, Michigan

Resistance to erythromycin (ermB+) and gentamicin

0.125/4

E. faecalis SF24413
(VRE)

Urine, Michigan

Resistant to erythromycin, gentamicin and vancomycin

0.125/4

E. faecalis SF28073
(VRE)

Urine, Michigan

Resistant to erythromycin, gentamicin and vancomycin

0.0625/8

E. faecalis HH22

Urine, Texas

Resistance to penicillin, erythromycin, tetracycline and
high levels of aminoglycosides

0.125/4

E. faecalis MMH594

Blood, Wisconsin

Resistance to erythromycin and gentamicin

0.125/4

E. faecalis SV587 (VRE)

Urine Missouri

Resistance to vancomycin

0.125/8

E. faecium E1162

Blood, France

Resistance to ampicillin.

0.25/16

Staphylococcus
spp

Streptococcus spp

E. faecium E0120 (VRE)

Ascites ﬂuid, Netherlands

Resistant to gentamicin and vancomycin

0.5/32

E. faecium ERV102
(VRE)

Oral sputum, Colombia

Resistant to ampicillin and vancomycin, and displays
high levels of resistance to streptomycin

0.5/16

E. faecium ATCC6569

Human feces

-

1/32

E. faecium ATCC
700221 (VRE)

Human feces, Connecticut

Resistant to vancomycin and teicoplanin

0.5/1

MSSA (NRS 72)

United Kingdom

Resistant to penicillin

0.25/0.5

MRSA (NRS 384)

United States (Mississippi)

Resistant to erythromycin, methicillin, and tetracycline

0.125/
0.125

MRSA (NRS119)

United States (Massachusetts)

Resistant to linezolid

0.125/0.25

MRSA (NRS 123)

United States

Resistant to methicillin; susceptible to nonbeta-lactam
antibiotics

0.25/0.5

MRSA (NRS194)

United States (North Dakota)

Resistant to methicillin

0.25/1

MRSA (NRS108)

France

Resistant to gentamicin

0.25/0.25

MRSA (NRS70)

Japan

Resistant to clindamycin, erythromycin and
spectinomycin

0.25/0.25

VISA (NRS 1)

Japan

Resistant to aminoglycosides and tetracycline
(minocycline)

0.125/
0.125

VISA (NRS 19)

United States (Illinois)

Glycopeptide-intermediate S. aureus

0.25/0.025

VRSA11a

United States

Resistant to erythromycin and spectinomycin

0.125/0.25

VRSA11b

United States

Resistant to erythromycin and spectinomycin

0.25/0.25

VRSA12

United States

Resistant to vancomycin

0.25/0. 5

VRSA13

United States

Resistant to vancomycin

0.25/0.25

Streptococcus pyogenes
ATCC 12344

-

Quality control strain

0.5/1

Streptococcus
agalactiae MNZ938

Human blood

Beta-hemolytic, Serogroup: Group B

0.5/0.5

Streptococcus
agalactiae MNZ 933

Human blood

Beta-hemolytic, Serogroup: Group B

0.5/0.5

Streptococcus
agalactiae MNZ 929

Human blood

Beta-hemolytic, Serogroup: Group B

0.5/0.5
(Continued)
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Table 1. (Continued)
Bacterial Strains

Strain ID

Source

Phenotypic Characteristics

MIC/MBC
(μg/ml)

Gram-negative
bacteria

Acinetobacter baumannii
ATCC BAA1605

MDR strain isolated from the
sputum of a Canadian soldier

Resistant to ceftazidime, gentamicin, ticarcillin,
piperacillin, aztreonam, cefepime, ciproﬂoxacin,
imipenem and meropemem

16/ND

E. coli O157:H7 ATCC
700728

Quality control strain

-

32/ND

Salmonella Typhimurium
ATCC 700720

Isolated from a natural source

-

32/ND

Klebsiella pneumonia
ATCC BAA 2146

Human urine

Clinical isolate New Delhi Metallo- β-Lactamase (NDM1) positive

64/ND

Pseudomonas
aeruginosa ATCC 9721

Quality control strain

-

>256/ND

VRE: vancomycin-resistant Enterococcus; MSSA: methicillin-sensitive S. aureus; MRSA: methicillin-resistant S. aureus; VISA: vancomycin-intermediate S.
aureus; VRSA: vancomycin-resistant S. aureus; ND: not determined
doi:10.1371/journal.pone.0133877.t001

Intracellular infection assay
J774A.1 murine macrophage-like cells were seeded at a density of 20,000 cells per well in 96-well
tissue culture plates. Cells were infected with MRSA USA300 (NRS 384–0114; ST-8) for 30 min
at a 1:100 multiplicity of infection (MOI). Then the cells were washed three times with DMEM
medium containing 10 IU lysostaphin to kill the extracellular bacteria [12]. Drugs (vancomycin,
linezolid and EB) were added at a concentration of 1 μg/ml to the DMEM medium supplemented
with 10% FBS and 4 IU lysostaphin. After 24 h incubation, the cells were washed three times
with phosphate buffered saline (PBS) and lysed with 0.1% Triton X-100. Lysates were diluted and
plated on TSA plates and MRSA colony forming units (CFU) were counted.

Toxicity assay
The toxicity assays were performed in cell culture and C. elegans. (a) Cell culture: J774A.1 murine
macrophage-like cells at a density of 20,000 cells per well were seeded and allowed to adhere in a
96-well tissue culture plate in DMEM media containing 10% FBS overnight. EB at various
concentrations ranging from 0 to 256 μg/ml were added to the cells in DMEM media with FBS.
After 24 h incubation with the drug, cells were washed with PBS and the MTS assay reagent,3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) in
DMEM medium was added and incubated for 4 h at 37°C. Absorbance was measured at 490 nm
using ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA). Cell viability after
treatment with EB was expressed as a percentage of the control, DMSO. (b) C. elegans: Temperature-sensitive C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) was used for toxicity studies and
the worms were synchronized as described before [13]. Synchronized L4-stage worms were resuspended in buffer containing 50% M9 buffer and 50% TSB. Then 100 μl of the buffer containing
approximately 15–20 worms were deposited in each well in 96-well plates and EB (4 and 8 μg/ml)
and vancomycin (8 μg/ml) were added. Worms were counted daily for three days and the percent
of live worms was calculated in each group. At least triplicate wells were used for each treatment

Cell-free bacterial and mammalian transcription/translation assay
The cell-free bacterial translation and mammalian translation assays were performed by the
commercially available Escherichia coli S30 System and Rabbit Reticulocyte Lysate System
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(Promega), respectively. The assays were performed as described by the manufacturer, in conjunction with appropriate positive control (chloramphenicol) and negative control (ampicillin)
antibiotics. In bacterial translation assay, the reaction mixtures were incubated at 37°C for 1 h.
Mammalian translation assay reaction mixtures were incubated at 30°C for 1 h. Luciferase
assay reagent was added to the reaction and the intensity of the luminescence was measured by
luminescence microplate reader (FLx800 BioTek Instruments, Inc. Winooski, Vermont)
according to the manufacturer’s instructions. Average luciferase readout of protein production
from two replicates from two independent experiments was calculated.

Mitochondrial biogenesis assay
The mitobiogenesis assay was done using In-Cell ELISA Kit (MitoSciences Inc., Eugene, OR)
as per the manufactures instruction [14]. Briefly, J774A.1 cells were seeded (40,000 cells per
well) in 96-well plates for overnight. EB and control antimicrobials (chloramphenicol and
ampicillin) were added to the cells and the cells were allowed to grow for approximately 3 days
with the drugs. Media were removed and cells were washed with PBS, then fixed with 4% paraformaldehyde. After fixing, cells were washed with PBS and permeabilization and blocking
processes were done according to the manufacturer’s instructions. Primary antibodies to detect
the levels of two proteins (subunit I of Complex IV (COX-I), which is mitochondrial DNA
(mtDNA)-encoded, and the 70 kDa subunit of Complex II (SDH-A), which is nuclear DNA
(nDNA)-encoded were added and incubated for overnight at 4°C. After incubation, cells were
washed with PBS and secondary antibodies were added and incubated at room temperature for
1 h. The expression of SDH-A and COX-1 were measured after washing and development at
405 nm and 600 nm wavelength, respectively. The ratio between COX-I and SDH-A was calculated and the percent of inhibition of mitochondrial biogenesis was measured.

Efficacy of EB in infected animal model (C. elegans)
L4-stage worms of C. elegans AU37 (sek-1; glp-4) strain (glp-4(bn2) were used to test the antimicrobial efficacy of EB as described before [13]. Briefly, worms were infected with MRSA
USA300 (NRS 384–0114; ST-8) in nematode growth media agar plate for 8 h at room temperature. After 8 h of infection, worms were collected and washed with M9 buffer four times before
incubation with the drugs. Worms were transferred to 96-well plates (20 worms per well) and
the drugs (EB and vancomycin) were added to the wells in triplicates to achieve a final concentration of either 4 or 8 μg/ml. After 24 h incubation with the drugs, worms were transferred to
2-ml centrifuge tubes, washed four times with PBS and 100 mg 1.0-mm silicon carbide particles
(Biospec Products, Bartlesville, OK) were added to each tube. The tubes were vortexed for one
minute at maximum speed to disrupt the worms without affecting bacterial survival [13]. The
resulting suspension was diluted and plated onto MSA plates to count the MRSA CFU. The
total CFU obtained from each well was divided by the number of worms in respective wells
and the results were expressed as percent of bacterial reduction per worm.

Synergistic activities of EB with conventional antibiotics in vitro and in
cell culture
(a) In vitro synergistic assay: The synergistic activities of EB with conventional antibiotics were
evaluated using the Bliss Independence Model as described before [4, 15]. Briefly, the optical
density of the bacteria grown in the presence of antibiotics and EB (fAB), antibiotics alone (fA0),
EB alone (f0B) and in the absence of drugs (f00) were measured and a degree of synergy (S) was
calculated using the formula: S = (fA0/f00)(f0B/f00)-(fAB/f00). Positive and negative values represent the degree of synergism and antagonism, respectively. (b) Intracellular synergistic assay in
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J774A.1 cells: J774A.1 cells were seeded and infected as described before under intracellular
infection assay. EB at concentration of 0.5 μg/ml was added to infected cells alone or in in
combination with control antibiotics such as linezolid (4 μg/ml), clindamycin (1 μg/ml), vancomycin (4 μg/ml), chloramphenicol (4 μg/ml), erythromycin (8 μg/ml), rifampicin (0.5 μg/ml)
and gentamicin (1 μg/ml). Untreated cells, and cells treated with antibiotics alone were used
as a control. After 24 h incubation, the cells were lysed and intracellular MRSA CFU were
determined as described above. Percent bacterial reduction was calculated in relative to the
untreated groups. Combination therapy was compared with single antibiotic therapy treatment
groups.

Statistical analyses
Statistical analyses were done using Graph Pad Prism 6.0 (GraphPad Software, La Jolla, CA).
P values were calculated by the one-tailed Student t test. P values of < 0.05 were considered as
significant.

Results and Discussion
In vitro antibacterial assays
In an attempt to repurpose approved drugs as antimicrobial agents, we investigated the
antimicrobial activity of EB against various multidrug-resistant clinical isolates of Gram-positive and Gram-negative pathogens (Table 1). EB exhibited potent bactericidal activity, in a
nanogram range, against all tested Gram-positive strains regardless of their resistance phenotype. EB showed potent activity against clinical isolates of Enterococcus faecalis and Enterococcus faecium with MIC90 of 0.5 μg/ml (see Table 1). EB also showed potent activity against
vancomycin-resistant strains of Enterococcus (VRE). Next, we tested the activity of EB against
the clinical isolates of multidrug-resistant S. aureus. EB showed more potent activity against
methicillin-sensitive S. aureus, MRSA, vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) strains than VRE with MIC90 of 0.25 μg/ml (see Table 1).
Finally, EB also showed potent activity against clinical isolates of Streptococcus pyogenes and
Streptococcus agalactiae with MIC of 0.5 μg/ml (see Table 1). On the other hand, EB did not
show potent antimicrobial activity (MIC 16 μg/ml) against Gram-negative pathogens,
including Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Salmonella Typhimurium, and Acinetobacter baumannii. The lack of activity of EB against Gram-negative pathogens might be due to its reduced ability to enter the cells due to outer membrane barrier or
the efflux pump rather than lack of target of EB inside Gram-negative bacteria [16–19].

Intracellular infection and cell toxicity
Some extracellular pathogens such as S. aureus are also capable of invading and surviving
within the mammalian host cells, leading to persistent chronic infections. Moreover, during
the S. aureus intracellular invasion phase, treatment with antimicrobials is very challenging
because most antibiotics do not actively pass through cellular membranes [20–27]. Therefore,
clinical failures of drug of choice, such as vancomycin, to cure S. aureus pneumonia have
exceeded 40% and have been attributed mainly to poor intracellular penetration of the drug
and consequently to the failure to kill intracellular MRSA in alveolar macrophages [28]. Hence,
finding antimicrobials that possess both extra- and intracellular activity would be an optimum
strategy to treat such invasive intracellular S. aureus infections. Therefore, we investigated if EB
possesses intracellular anti-staphylococcal activity. As shown in Fig 1, EB at a concentration of
1 μg/ml significantly reduced the intracellular MRSA by 32%. In contrast, the conventional
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Fig 1. Activity of EB, vancomycin and linezolid against intracellular MRSA USA300 in J774A.1 cells.
MRSA infected J774A.1 cells were treated with EB and control antibiotics (vancomycin and linezolid) for 24 h
and the percent bacterial reduction was calculated compared to untreated control groups. The results are
given as means ± SD (n = 3). P values of (**, #  0.05) are considered as significant. EB was compared to
controls (**) and to antibiotics (#).
doi:10.1371/journal.pone.0133877.g001

antimicrobials such as vancomycin and linezolid (drugs of choice for treatment of MRSA infections) at the same concentration reduced intracellular MRSA by only 16% and 21%, respectively. EB toxicity was assayed against J774A.1 cells at a concentration ranging from 0 to
256 μg/ml for 24 h. The results shown in Fig 2 indicate that EB does not show toxicity up to
64 μg/ml. The concentration of the EB that causes 50% toxicity (half inhibitory concentration:
IC50) in J774A.1 cells is 95.68 ± 4.12 μg/ml. This value is more than 380-fold higher than the
concentration required to inhibit MRSA. Collectively, these results suggest that EB has great
potential for treatment of S. aureus infections where not only is eradication of extracellular bacteria important, but the killing of intracellular bacteria is also critical [29].

Cell-free bacterial transcription/translation assay
Antimicrobials that target microbial protein synthesis such as oxazolidinones and lincomycins
are considered excellent choices for the treatment of toxin-mediated bacterial infections caused
by S. aureus, such as toxic shock syndrome (TSS) and pneumonia [30–33]. In addition to the
suppression of S. aureus toxins such as Panton-Valentine leucocidin (PVL), α-hemolysin (hla),
and toxic shock syndrome toxin–1 (TSST-1), these antimicrobials also reduce excessive hostinflammatory responses associated with these toxins [34, 35]. Hence, protein synthesis inhibitors are often preferred in clinical practice for the treatment of toxin-associated staphylococcal
infections [30–33]. We tested the effects of EB in our study on bacterial, mammalian and mitochondrial protein-synthesis. For bacterial protein-synthesis inhibition, we used E. coli cellular
extracts in a transcription and translation assay that monitors protein production via luciferase
readout. Unlike the antibiotic ampicillin that inhibits cell wall synthesis, EB strongly inhibited
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Fig 2. Cytotoxicity assay in murine macrophage-like cells (J774A.1) cells. J774A.1 cells were treated
with different concentration of EB ranging from 0 to 256 μg/ml. DMSO was used as a negative control. Cell
viability was measured by MTS assay and IC50 of EB to cause cytotoxicity in J774A.1 cells was calculated.
doi:10.1371/journal.pone.0133877.g002

bacterial transcription/translation process similar to chloramphenicol antibiotic that inhibits
protein synthesis (Fig 3A). EB inhibited bacterial protein synthesis in the cell-free transcription-translation, exhibiting IC50 of 0.25±0.10 μg/ml which is comparable to IC50 of chloramphenicol antibiotic 0.48 ± 0.10 μg/ml (Fig 3B). These results indicate that EB acts by a favorable
mechanism of action and inhibits bacterial protein synthesis and, most likely, toxin production.
However, inhibition of bacterial protein synthesis does not exclude other possible mechanism
of action of EB.

Cell-free mammalian transcription/translation assay and mitochondrial
biogenesis
Due to concern about the possible mitochondrial toxicities associated with many antibacterial
protein synthesis inhibitors such as linezolid and chloramphenicol [36–42], we tested the effect
of EB on the inhibition of eukaryotic transcription/translation process using the rabbit reticulocyte lysate system with the cellular components necessary for mammalian protein synthesis
[43, 44]. As shown in Fig 4A, EB showed high safety profile with IC50 of mammalian protein
synthesis of 166.09 ± 12.08 μg/ml. This value is more than 660-fold higher than the concentration required to inhibit protein synthesis in bacteria. However, in order to test the effect of
EB more specifically on mitochondrial biogenesis and to confirm the above in vitro results
obtained from rabbit reticulocyte lysate system, we measured the effect of EB on mitochondrial
protein synthesis directly within the mammalian cells. In-cell ELISA was performed in J774A.1
cells treated with EB and chloramphenicol for three days to detect the levels of mtDNAencoded COX-I and nDNA-encoded SDH-A proteins. Results shown in Fig 4B indicate that
EB had no significant inhibition (less than 10%) of mitobiogenesis, similar to the effect of
ampicillin, which does not interfere with mitochondrial protein synthesis process. At the same
time, chloramphenicol had more than 60% inhibition of mitochondrial protein synthesis.
These results provide valuable information about EB’s safety profile and the lack of interference
with mammalian protein synthesis and mitobiogenesis.
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Fig 3. Effects of EB on coupled transcription-translation (TT) in S30 extracts from E. coli. (a) Average luciferin protein production in the presence of EB,
ampicillin and chloramphenicol at the concentration of 2 μg/ml were shown. The results are given as means ± SD (n = 3). (b) Concentration dependent TTinhibition of EB and chloramphenicol were shown. IC50 of the drugs required to inhibit 50% TT-activity were determined. P values of (**  0.05) are
considered as significant.
doi:10.1371/journal.pone.0133877.g003
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Fig 4. Effects of EB on mammalian protein synthesis. (a) Concentration dependent inhibition of protein synthesis were determined using rabbit
reticulocyte lysate extract system. IC50 of the EB required to inhibit 50% translational activity were determined. (b) Effect of EB, chloramphenicol and
ampicillin on mitobiogenesis. J774A.1 cell In cell- ELISA was carried out in the presence and absence of these drugs, and the levels of mitochondrial (mt)DNA encoded protein (COX-I) and nuclear-DNA encoded protein (SDH-A) were quantified. Ratio of COX-I and SDH-A were calculated and the results were
shown as percent inhibition of mitochondrial biogenesis.
doi:10.1371/journal.pone.0133877.g004
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Efficacy of EB in infected animal model (C. elegans)
To investigate if the potent in vitro antimicrobial activity of EB translates to antimicrobial efficacy in vivo, we tested antimicrobial efficacy of EB in an infected C. elegans whole animal
model. A whole animal model, such as C. elegans, represents a great platform for drug discovery and enables simultaneous assessment of efficacy and toxicity of the tested drugs. Additionally, using a C. elegans model reduces the associated cost of drug discovery and lowers the
burden for extensive animal testing [13, 45]. Prior to testing the efficacy of treatment with EB
in infected C. elegans, we tested toxicity of EB in non-infected C. elegans. As shown in Fig 5A,
treatment of C. elegans with EB at 4 and 8 μg/ml for three days did not show any significant
toxicity, similar to control groups. With no observable toxicity noticed in EB treated groups at
a concentration of 4 and 8 μg/ml, we moved forward with an in vivo infection model using C.
elegans infected with MRSA. As seen in Fig 5B, treatment with EB had a significant reduction
in bacterial load when compared to untreated groups. EB at a concentration of 4 and 8 μg/ml
significantly reduced the mean bacterial count by 56% and 85%, respectively. Moreover, treatment with EB at a concentration of 8 μg/ml showed comparable effect to treatment with the
drug of choice vancomycin in reducing MRSA burden in infected C. elegans. Taken together,
these results show that EB exhibits potent in vivo antistapylococcal efficacy in MRSA-infected
C. elegans.

Synergistic activities of EB with conventional antibiotics in vitro and in
cell culture
After confirming that EB has a potential use as an antibacterial agent for the treatment of
infections caused by multidrug resistant pathogens, it was important to explore the synergistic
relationship of EB with conventional antibiotics in vitro and in cell culture. With the rapid
emergence of multidrug-resistant strains of S. aureus, monotherapy with single antibiotic has
become less effective [46, 47]. Therefore, alternative strategies such as combinational therapy
have been used in the healthcare setting to improve the morbidity associated with MRSA infections and to reduce the likelihood of emergence of resistant strains [1, 46, 48, 49]. To ascertain
whether EB has the potential to be combined in vitro and in cell culture with conventional antimicrobials such as linezolid, clindamycin, vancomycin, chloramphenicol, erythromycin, rifampicin, and gentamicin against MRSA USA300, we used the in vitro Bliss independence model
of synergism and infected cell culture assay [15]. In vitro results from the Bliss independence
model of synergism are presented in Fig 6A. EB was found to exhibit a synergistic relationship
with all tested conventional antimicrobials in vitro against MRSA USA300. Results of synergistic relationship of EB with conventional antimicrobials in infected cell culture against intracellular MRSA USA300 are presented in Fig 6B. Conventional antimicrobials (clindamycin,
erythromycin, and rifampicin) showed synergistic activity when combined with EB and significantly reduced intracellular MRSA when compared to monotherapy. However, EB did not
show synergistic activity with linezolid, vancomycin, chloramphenicol, or gentamicin in clearing intracellular MRSA. Identifying antibiotics that can be synergistically paired with EB can
potentially prolong the clinical utility of these antibiotics and reduce the likelihood of emergence of resistant strains.
In conclusion, we have successfully explored the potential applications of EB in vitro, in cell
culture, and in vivo to combat multidrug-resistant Gram-positive pathogens, especially MRSA.
We demonstrated that EB inhibits the bacterial translation process without affecting mitochondrial biogenesis. Additionally, we demonstrated the efficacy of EB in vivo in a C. elegans
MRSA-infected model. Finally, we identified potential antibiotics that can be synergistically
combined with EB to prolong the clinical utility of these antibiotics and reduce the likelihood
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Fig 5. Evaluation of toxicity and antimicrobial efficacy of EB in C. elegans model. (a) C. elegans strain glp-4; sek-1 (L4-stage) were grown for three days
in the presence of EB (4μg and 8 μg/ml) and vancomycin (8 μg/ml). Live worms were counted and the results were expressed as percent live worms in
relative to the untreated control groups. (b) MRSA USA300 infected L4-stage worms were treated with EB (4μg and 8 μg/ml) and vancomycin (8 μg/ml) for 24
h. Worms were lysed and the CFU were counted and the percent bacterial reduction per worm in treated groups were calculated in relative to the untreated
control groups. P values of (**  0.05) are considered as significant.
doi:10.1371/journal.pone.0133877.g005

of the emergence of resistant strains. Taken together, our study results demonstrate that EB,
with its potent antimicrobial activity and safety profiles, might be a potential candidate drug
for systemic and (or) topical applications to treat multidrug resistant Gram-positive bacterial
infections alone or in combination with other antibiotics and should therefore be further clinically evaluated.
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Fig 6. Synergistic activities of EB with conventional antibiotics in vitro and in cell culture. (a) The Bliss
Model for Synergy confirms the in vitro synergism with conventional antimicrobials (gentamicin, rifampicin,
erythromycin, chloramphenicol, vancomycin, clindamycin and linezolid) against MRSA USA300. Degree of
synergy was calculated in the presence of EB (0.0312 μg/ml) in combination with sub-inhibitory concentrations
of conventional antimicrobials. (b) Synergistic activity of EB with conventional antimicrobials in infected cell
culture. Efficacy of EB (0.5μg/ml) in combination with linezolid (4μg/ml), clindamycin (1μg/ml), vancomycin
(4μg/ml), chloramphenicol (4μg/ml), erythromycin (8μg/ml), rifampicin (0.5μg/ml) and gentamicin (1μg/ml) in
clearing intracellular MRSA USA300 was determined in J774A.1 cells. Percent bacterial reduction was
calculated in relative to the untreated groups. The results are given as means ± SD (n = 3). Combination
therapy was compared to monotherapy and the P values of (**,  0.05) are considered as significant.
doi:10.1371/journal.pone.0133877.g006
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